Related Experiment Video
Updated: Apr 21, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials
A D Hartkopf1, T Fehm1, M Wallwiener2
1Department of Obstetrics and Gynecology, University of Tübingen, Tübingen.
Abstract:
Oncolytic viruses are replication competent "live" viruses. They infect tumor cells, replicate highly selective inside and thereby destroy them. Because of the enormous advances in the field of genetic engineering and biotechnology during the last decade, virotherapy is increasingly used within clinical trials and proved to be safe and effective. In particular, treatment of ovarian cancer patients is one main focus of research. On the one hand, this is due to the poor prognosis of this dismal entity, resulting in the urgent need for novel therapeutics. On the other hand, as ovarian cancer typically spreads within the peritoneal cavity, intraperitoneal administration of oncolytic viruses is feasible. This paper provides an overview of promising results from clinical trials to treat ovarian cancer patients with oncolytic viruses.
Insights
Oncolytic virus therapy offers a promising new treatment for ovarian cancer. These live viruses selectively destroy cancer cells, showing safety and effectiveness in clinical trials for this hard-to-treat disease.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Oncolytic viruses are live viruses engineered to selectively infect and replicate within tumor cells, leading to cancer cell destruction.
- Virotherapy has advanced significantly due to genetic engineering and biotechnology, leading to increased use in clinical trials.
- Ovarian cancer has a poor prognosis, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To provide an overview of the promising results from clinical trials investigating oncolytic virus therapy for ovarian cancer.
- To highlight the potential of virotherapy as a safe and effective treatment modality for ovarian cancer patients.
Main Methods:
- Review of clinical trial data on oncolytic virus therapy for ovarian cancer.
- Focus on intraperitoneal administration feasibility due to ovarian cancer's typical spread within the peritoneal cavity.
Main Results:
- Oncolytic virus therapy has demonstrated safety and efficacy in clinical trials for ovarian cancer.
- Promising results indicate a potential new avenue for treating this aggressive cancer.
Conclusions:
- Oncolytic virus therapy is a viable and promising approach for ovarian cancer treatment.
- The feasibility of intraperitoneal administration makes virotherapy particularly suitable for ovarian cancer.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:11Clinical Trials: Overview
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...